VAVadim E. Askarov

Vadim E. Askarov

*This is an algorithmically generated author record based on publicly available information.

Vadim E. Askarov has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intracranial activity characteristics of third-generation ALK inhibitor

    by A. F. Nasretdinov, A. V. Sultanbaev, K. V. Menshikov, V. E. Askarov, Sh. I. Musin, A. A. Izmailov, А. Ф. Насретдинов, А. В. Султанбаев, К. B. Меньшиков, В. Е. Аскаров, et al.

    Introduction. Intracranial involvement in ALK-positive non-small cell lung cancer is associated with poor prognosis and resistance to certain therapies due to the blood-brain barrier. Third-generation tyrosine kinase inhibitors, particularly lorlatinib, demonstrate high efficacy due to their lipophilicity and low affinity for P-glycoprotein. Aim. To present a clinical case of successful use of lorlatinib for controlling intracranial progression in a patient with ALKpositive non-small cell lung cancer after developing resistance to alectinib, as well as to analyze the factors contributing to the antitumor response in the central nervous system. Mat erials and methods. We describe a case of a female patient born in 1963 diagnosed with stage IVB peripheral lung adenocarcinoma (T1cN3M1c, oss, cer), ALK-positive. After disease progression on alectinib therapy (development of multiple brain metastases), lorlatinib was prescribed at a dose of 100 mg per day, followed by dose reduction to 75 mg per day. Efficacy was assessed using brain MRI and chest CT. R e s u l t s and di sc u ssi on. While receiving lorlatinib, the patient achieved a complete intracranial response, confirmed by MRI at 3, 6, 9, and 12 months of follow-up. The duration of central nervous system tumor growth control after switching therapy was 12 months or more. Adverse events (grade 1 hypercholesterolemia, grade 2 peripheral neuropathy and edema) were managed by dose reduction to 75 mg per day without loss of efficacy. Overall lorlatinib showed high intracranial and an expected toxicity Conclusion. Lorlatinib is a highly effective agent for overcoming intracranial resistance in patients with ALK-positive lung cancer who progress on alectinib. This case supports the use of lorlatinib in the second-line setting for isolated central nervous system progression, potentially avoiding radiotherapy and its associated complications.

  • Results of the use of immune checkpoint inhibitors in the treatment of small cell lung cancer in real-life clinical practice: results of a single-center observational study

    by A.V. Sultanbaev, I.A. Tuzankina, A.F. Nasretdinov, K.V. Menshikov, V.E. Askarov, Sh.I. Musin, N.I. Sultanbaeva, A.A. Izmailov, I.A. Menshikova, D.A. Kudlay

    Small cell lung cancer (SCLC) is an aggressive tumor with early metastasis and a low 5-year survival rate (6.4%). Despite the use of PD-L1 inhibitors (atezolizumab, durvalumab) in combination with chemotherapy, outcomes remain unsatisfactory due to resistance and patient heterogeneity. Objective. To evaluate the effectiveness of immunochemotherapy (atezolizumab+carboplatin/etoposide) in real-world clinical practice in patients with metastatic SCLC. Material and methods. Data from 98 patients (87 men, 11 women, median age 62 years) over 50 months (2020—2024) were analyzed. Treatment regimen: carboplatin (AUC5), etoposide (100 mg/m²), and atezolizumab (1200 mg) every 3 weeks (4 cycles), followed by maintenance therapy. Progression-free survival (PFS), overall survival (OS), and the impact of metastases/comorbidities were assessed. Results. Median PFS was 6 months, OS was 12 months. Partial response was observed in 60.2%, stable disease in 23.5%, disease progression in 13.3%, and complete response in 3.1%. Metastases in the liver, bones, peritoneum, and kidneys significantly reduced PFS and OS (p< 0.05). Comorbidities had no significant impact. Conclusion. The combination of atezolizumab with chemotherapy demonstrates efficacy comparable to clinical trial data, but outcomes depend on metastasis location. Metastatic involvement of the liver, bones, and peritoneum is associated with a worse prognosis, highlighting the need for personalized treatment approaches.


  • Open Access

    Efficacy of combination immunotherapy in patients with generalized uveal melanoma: real clinical practice

    by A. V. Sultanbaev, I. A. Tuzankina, A. F. Nasretdinov, N. I. Sultanbaeva, K. V. Menshikov, Sh. I. Musin, V. M. Zabelin, R. T. Ayupov, V. E. Askarov, R. R. Rakhimov, et al.

    Introduction. Uveal melanoma is a rare malignant neoplasm that develops from melanocytes of the choroid of the eyeball. It occupies a leading position in the structure of intraocular malignant neoplasms.Aim. Тo analyze real-world clinical practice data on the use of nivolumab in combination with ipilimumab to treat patients with metastatic uveal melanoma.Materials and methods. Fifteen patients with metastatic uveal melanoma received therapy with nivolumab and ipilimumab. The median age of patients was 53 years, the minimum age was 24 years, and the maximum was 71 years. The analysis included 9 (60%) men and 6 (40%) women. Evaluation of the functional status showed that 4 (26.7%) patients had ECOG 0 points, 6 (40%) – ECOG 1 and 5 (33.3%) – ECOG 2.Results. The median relapse-free survival after enucleation of the eye was 61 months. Objective response to immunotherapy was achieved in 33.3% of patients, and the disease control rate was 86.6%. However, 4 (26.6%) patients discontinued therapy due to hepatotoxicity. The study noted that the median overall survival from the start of therapy with nivolumab in combination with ipilimumab reaches 8 months. It was found that the functional status of patients and the response to therapy are important predictors of survival, where patients with better indicators have a significantly higher life expectancy. Thus, patients with ECOG 0 show a median overall survival of 18 months.Conclusion. Immune checkpoint inhibitors remain the mainstay of treatment for patients with metastatic uveal melanoma. Combined immunotherapy with nivolumab and ipilimumab can be considered as a possible treatment option for this category of patients in conditions of limited therapeutic options.

  • Open Access

    Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case

    by V. E. Askarov, A. V. Sultanbaev, K. V. Menshikov, V. S. Chalov, N. I. Sultanbaeva, I. A. Menshikova

    Introduction. Cutaneous melanoma is a highly aggressive malignancy with a significant risk of metastasis. Current treatment strategies include surgical resection, immunotherapy, and targeted therapy directed at mutations in the MAPK/ ERK pathway, particularly BRAF V600E. Despite the efficacy of dual BRAF/MEK inhibition, the rapid development of drug resistance remains a challenge, prompting interest in combination immunotherapy plus targeted therapy. Aim. This study aimed to evaluate the efficacy and tolerability of triple therapy, involving atezolizumab, vemurafenib, and cobimetinib in patients with BRAF V600 mutation-driven metastatic melanoma following failure of prior lines of therapy. Materials and methods. We present a detailed case report of a patient with metastatic cutaneous melanoma who achieved disease stabilization for 27 months following surgery and first-line therapy with dabrafenib and trametinib. After subsequent progression, second- and third-line therapies with pembrolizumab followed by pembrolizumab and lenvatinib were administered; however, both therapies proved ineffective. Fourth-line therapy with atezolizumab, vemurafenib, and cobimetinib demonstrated a significant clinical response. Results and discussion. Following six months of triple therapy, positron emission tomography/computed tomography (PET/CT) confirmed complete metabolic regression of the previously identified lesions, including those in the intrathoracic lymph nodes and pulmonary metastases. The treatment was well tolerated, with no grade 3–4 adverse events. Conclusion. This clinical case highlights the potential of the atezolizumab, vemurafenib, and cobimetinib therapy in patients with pretreated BRAF V600E-mutated metastatic melanoma. This regimen may benefit patients with acquired resistance to BRAF/MEK inhibitors and immune checkpoint inhibitors. The findings underscore the importance of personalized treatment strategies and the need for further research in this area.

  • 5’UTR gene regions in germline DNA sequencing panels: lessons from the analysis of breast and ovarian cancer patients of Tatar and Bashkir ethnic origin

    by Anna P. Sokolenko, Aigul R. Venina, Alexandr A. Romanko, Evgenia V. Belogubova, Alexandr V. Sultanbayev, Vadim E. Askarov, Gulnara K. Mukhamediarova, Elvina Kh. Bakaeva, Maria V. Syomina, Tatiana Yu. Velyukhova, et al.

    Background Tatars and Bashkirs are large and closely related ethnic communities that reside in the territory of the Russian Federation but have managed to preserve their national identity through the course of history. Methods This study included 446 Tatars, 53 Bashkirs, and 26 women of mixed Tatar-Bashkir ethnicity. Germline DNA analysis was performed for 349 breast cancer (BC) patients with clinical features of hereditary disease (family history, or young onset ( T, was observed in 11 subjects. Among 27 women with BRCA2 PVs, six and five women were carriers of the c.-39-1_-39del and c.468dup variants, respectively. The loss-of-heterozygosity (LOH) test confirmed the pathogenic nature of the c.-39-1_-39del [rs758732038] allele, which is located in the 5’UTR of BRCA2. Analysis of other BC-associated genes revealed single instances of PVs affecting PALB2, TP53, ATM, RAD51, and RAD51D genes. Conclusion Tatars and Bashkirs, which are ethnically and religiously separated from Russians, carry an unexpectedly high proportion of Slavic BRCA1/2 founder alleles. The identification of recurrent Tatar/Bashkir BRCA2 pathogenic 5’UTR variant c.-39-1_-39del calls for a systematic analysis of regulatory regions of cancer-predisposing genes in patients with missing heritability.


  • Open Access

    Palbociclib in real clinical practice: Results of a single-center observational study

    by A. V. Sultanbaev, I. V. Kolyadina, A. F. Nasretdinov, K. V. Menshikov, V. E. Askarov, Sh. I. Musin, K. T. Akhmetgareeva, N. I. Sultanbaeva, V. M. Zabelin, R. T. Ayupov, et al.

    Introduction. A breakthrough in the treatment of metastatic hormone-dependent (HR+) breast cancer was combination endocrine therapy with CDK4/6 inhibitors, which significantly prolonged the tumor response time to treatment and the median survival before progression. The effectiveness of combination endocrine therapy in real-life practice is of particular interest due to the wider population of patients with different somatic status and comorbidity, often not included in randomized trials.Aim. Analyze of palbociclib using for treating patients with HR+/HER2– advanced breast cancer (mBC) at the Republican Clinical Oncology Dispensary.Materials and methods. Data from 323 patients were analyzed. Our study examined the effectiveness of combination endocrine therapy with palbociclib in patients with metastatic HR+ HER2– breast cancer. Data on the clinicopathological characteristics of patients and disease progression during palbociclib administration were obtained by reviewing clinical data from patient records and radiological/pathological examination reports.Results. The median age of patients included in the study was 62 years. When assessing the antitumor response, a partial response was recorded in 54 patients (16.7%), stabilization in 212 patients (65.6%), and progression in 57 patients (17.8%). The median progression-free survival was 13 months. Grade 3 adverse events were noted in 23 patients: neutropenia in 21.7% of cases, hepatotoxicity in 47.8% of cases, cardiotoxicity in 17.4% of cases, and coagulopathy in 4.3%. No patient discontinued therapy due to adverse events. The best treatment results were achieved by patients who used the combination of palbociclib with an endocrine partner as the first line of treatment for advanced stage.Conclusion. This analysis of real-world data on the use of palbociclib in real-world clinical practice confirms the RCT data on the efficacy and safety of using CDK4/6 inhibitors for the treatment of patients with HR+ HER2- mBC.


  • Open Access

    Evolution of therapy for ALK-positive lung carcinomas: Application of third-generation ALK inhibitors in real clinical practice

    by A. F. Nasretdinov, A. V. Sultanbaev, Sh. I. Musin, K. V. Menshikov, R. T. Ayupov, A. A. Izmailov, G. A. Serebrennikov, V. E. Askarov, D. V. Feoktistov

    Lung cancer is currently a heterogeneous group of diseases, whose heterogeneity is determined not only by its phenotypic, but also by its genetic profile. A special place is occupied by subtypes that have driver mutations. Due to new antitumor agents – small molecule inhibitors – it has become possible to significantly increase patients’ chances of survival. The diagnostic panel most often includes mutations in the EGFR, ALK, ROS1, BRAF genes; somewhat less frequently, genetic changes in MET, KRAS, HER2, NTRK, etc. are determined. This distribution is most likely explained by the availability of appropriate inhibitors. The article provides an overview of different generations of ALK inhibitors known in the Russian Federation, among them the most famous: crizotinib, ceritinib, alectinib and lorlatinib. These drugs are included in the clinical guidelines for the treatment of ALK-positive lung carcinomas of all major oncology societies. The article describes the results of registration studies proving the advantage of ALK inhibitors over standard therapy, including the results of the CROWN study. In this study, the latest generation of ALK inhibitors, lorlatinib, demonstrates superiority over crizotinib, with a 73% reduction in the risk of progression or death and better intracranial response rates. A description of a clinical case of treatment of metastatic lung cancer using the third generation ALK inhibitor lorlatinib is provided. The drug was prescribed in the first line of therapy. The patient’s treatment outcome indicates high efficacy of lorlatinib in the first-line treatment of ALK translocation-positive lung cancer, along with low toxicity. The treatment period has already been more than 70 months and the patient continues therapy at the time of the last control. A complete response to lorlatinib therapy was recorded. During treatment, the following adverse events were recorded: hypertriglyceridemia, grade 1 toxicity, hypercholesterolemia, grade 2 toxicity, increased liver transaminases, grade 1 toxicity.

  • Open Access

    Combined Use of Cabozantinib and Nivolumab in Clinical Practice

    by V. E. Askarov, A. V. Sultanbaev, K. V. Menshikov, Sh. I. Musin, N. I. Sultanbaeva, E. V. Popova, I. A. Menshikova

    Комбинированное применение кабозантиниба и ниволумаба в клинической практике

  • Open Access

    The use of ribociclib in real clinical practice: results of a single-center observational retrospective study

    by A. V. Sultanbaev, I. V. Kolyadina, Sh. I. Musin, A. F. Nasretdinov, N. I. Sultanbaeva, K. V. Menshikov, I. A. Menshikova, V. E. Askarov, R. R. Rakhimov, D. O. Lipatov, et al.

    Introduction. The standard initial treatment for patients with hormone receptor positive, HER2 negative, metastatic breast cancer (HR+/HER2– mBC) involves the use of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy. The combination therapy has proven effectiveness in numerous Phase II and III randomized controlled trials (RCTs). Nonetheless, RCTs may not fully represent real-world clinical situations due to their stringent inclusion criteria, resulting in a specific patient population.Aim. Analyze of ribociclib using for treating patients with HR+/HER2– advanced breast cancer (mBC) at the Republican Clinical Oncology Dispensary.Materials and methods. Patients diagnosed with HR+/HER2– mBC who were treated in clinical routine with ribociclib in combination with different endocrine agents between 2016 and 2020 were identified and enrolled in this retrospective study. Clinicopathological characteristics and clinical outcomes were recorded with particular emphasis on ribociclib therapy course (progression-free survival (PFS), toxicity, dose reduction).Results. Data from n = 101 patients were evaluated. The mean patient age was 61 years. The study included 67 (66.3%) patients with progression after radical treatment and 34 (33.7%) patients with primary disseminated breast cancer. Dose reduction due to adverse events was performed in n = 14 cases (13.9%). Presence of prior therapy lines and lower ECOG status were associated with shorter PFS, whereas estrogen positivity and the choice of fulvestrant over aromatase inhibitor were positively associated with PFS. Metastatic pattern, progesterone positivity and dose reduction due to toxicity did not significantly impact on PFS.Conclusion. Our real-world data analysis on ribociclib treatment in Russian regional hospital supports data from RCTs regarding both treatment efficacy and safety of CDK4/6i for treatment of patients with HR+/HER2– mBC. Currently, by expanding our experience with CDK4/6 inhibitors in different groups of patients with mBC, we will be able to provide patients with optimal treatment options.